HomeAI · summaries
Storia in 2 fonti
With Elahere building steam, AbbVie nets FDA nod for another ImmunoGen cancer asset
As AbbVie continues to capitalize on its deal for ImmunoGen with the growth of commercial antibody-drug conjugate (ADC) Elahere, another of the acquired company’s clinical assets has crossed the FD | As AbbVie continues to capitalize on its deal for ImmunoGen with the growth of commercial antibody-drug conjugate Elahere, another of the acquired company’s clinical assets has crossed the FDA finish line.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
AbbVie clinches FDA approval for ultra-rare blood cancer ADC from ImmunoGen purchase
AbbVie said the FDA has approved an antibody-drug conjugate it obtained as a part of its $10.1 billion buyout of ImmunoGen for an ultra-rare but aggressive form of blood cancer.
- ·
fiercepharma.com
With Elahere building steam, AbbVie nets FDA nod for another ImmunoGen cancer asset
As AbbVie continues to capitalize on its deal for ImmunoGen with the growth of commercial antibody-drug conjugate (ADC) Elahere, another of the acquired company’s clinical assets…
